Clinical Report: Role of Insulin-like Growth Factor Binding Proteins in Metabolic Dysfunction-Related Steatotic Liver Disease
Overview
This report reviews the role of insulin-like growth factor binding proteins (IGFBPs) in metabolic dysfunction-associated steatotic liver disease (MASLD). It highlights their dual roles in metabolic protection and potential pathogenic effects, emphasizing their relevance as biomarkers and therapeutic targets.
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition that can progress to severe liver complications, including cirrhosis and hepatocellular carcinoma. The rising incidence of MASLD is closely linked to increasing rates of obesity and type 2 diabetes, making it a significant public health concern. Understanding the molecular mechanisms, including the role of IGFBPs, is crucial for developing effective interventions.
Data Highlights
No numerical data or trial data were provided in the source material.
Key Findings
IGFBP1 and IGFBP2 promote lipid oxidation and increase insulin sensitivity.
IGFBP3 and IGFBP5 restrain lipogenesis at early stages but promote hepatocellular injury during fibrosis.
IGFBP7 impairs insulin signaling and drives fibrosis through ferroptosis.
IGFBP4 and IGFBP6 are less characterized but may have roles in MASLD.
IGFBPs can serve as potential biomarkers for disease staging and therapeutic targets.
Clinical Implications
The findings suggest that IGFBPs could be utilized as biomarkers for assessing the progression of MASLD. Additionally, targeting specific IGFBPs may offer new therapeutic strategies for managing this disease.
Conclusion
The review underscores the complex roles of IGFBPs in MASLD, highlighting their potential as both biomarkers and therapeutic targets in the management of this increasingly prevalent condition.
